Epistem

The test is performed in less than an hour using a buccal cheek swab, and runs on Genedrive’s hand-held real-time PCR instrument.

The license was issued to the firm's distribution partner, Xcelris Labs, and Epistem intends to begin placing its Genedrive molecular platforms in the coming months.

NEW YORK (GenomeWeb) — Epistem said this week that it has successfully completed a clinical evaluation of its Genedrive molecular diagnostics platform and completed a regulatory submission with the Drug Controller General of India for its first test for the diagnosis of tuberculosis and rifampin

NEW YORK (GenomeWeb) — Epistem said today that it has entered into a collaborative funding agreement with the Global Health Investment Fund to support commercialization of Epistem's Genedrive molecular diagnostic platform and tuberculosis assay.

BD Diagnostics, a segment of Becton Dickinson, this week announced the availability of the US Food and Drug Administration-cleared BD MAX Enteric Bacterial Panel for use on the BD MAX system.

NEW YORK (GenomeWeb News) — Epistem said yesterday that it has entered into cooperative agreements with the US Air Force and Johns Hopkins University's Advanced Physics Laboratory to undertake combat evaluation of Epistem's Genedrive molecular handheld pathogen-detection device.

NEW YORK (GenomeWeb News) – UK biotech firm Epistem said today that it has received €1.5 million ($2 million) from the European Commission to develop point-of-care diagnostic tests for Hepatitis C as part of a €6 million, international project called the PoC HCV consortium.

NEW YORK (GenomeWeb News) – UK firm Epistem today announced its intention to raise £4.2 million ($6.7 million) in net proceeds in preparation of the launch of its molecular diagnostics platform and a tuberculosis assay.

UK-based molecular diagnostics developer Epistem said this week that Becton Dickinson will distribute Epistem's point-of-care assay for Mycobacterium tuberculosis and rifampin resistance on a global basis excluding India and the Indian sub-continent.

NEW YORK (GenomeWeb News) – Epistem said today that Becton Dickinson will distribute the firm's Mycobacterium tuberculosis test on a global basis, excluding India and the Indian Sub-Continent.

Pages

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.